Compare CURI & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CURI | ARCT |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | 42 | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.7M | 189.9M |
| IPO Year | N/A | 2019 |
| Metric | CURI | ARCT |
|---|---|---|
| Price | $3.03 | $8.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | $5.83 | ★ $27.70 |
| AVG Volume (30 Days) | 411.8K | ★ 507.1K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 10.92% | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,031,000.00 |
| Revenue This Year | $12.52 | N/A |
| Revenue Next Year | $15.31 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.30 | $5.85 |
| 52 Week High | $7.15 | $24.14 |
| Indicator | CURI | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 43.72 | 62.44 |
| Support Level | N/A | $6.90 |
| Resistance Level | $3.59 | $8.65 |
| Average True Range (ATR) | 0.15 | 0.42 |
| MACD | -0.01 | 0.15 |
| Stochastic Oscillator | 30.61 | 87.43 |
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. The firm's products and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, and Others. The majority of the revenue comes from the direct business and Content licensing. Geographically, the company generates the majority of its revenue from the United States.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.